Alvotech Expands Pipeline With 9 Biosimilar Candidates in Development
Alvotech files 2025 annual report with SEC, reporting five marketed biosimilars and nine additional candidates in development across therapeutic areas.
ALVOALVOWregulatory complianceForm 20-F